Q1 Sales & Earnings: An Opportunity For Clarity In An Uncertain Time
Johnson & Johnson is the first big pharmaceutical company to report first quarter financial results, and investors across the industry are interested in hearing how the COVID-19 pandemic is impacting the sector's fundamental business dynamics.
You may also be interested in...
AbbVie made only a slight adjustment to its earnings-per-share guidance despite expected Q2 downturn due to the pandemic. It sees Allergan’s aesthetic business as bouncing back quickly.
The company will cut 340 positions, primarily affecting Zulresso commercial operations, to save $170m, after announcing it will need to run new trials to support the regulatory plan for zuranolone.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.